Society of Hematologic Oncology's Annual Meeting

The FDA approved two gene therapies, the first of their kind, to treat patients aged 12 years and older with sickle cell disease.

The FDA approved two gene therapies, the first of their kind, to treat patients aged 12 years and older with sickle cell disease.

The FDA approved two gene therapies, the first of their kind, to treat patients aged 12 years and older with sickle cell disease.

The FDA approved two gene therapies, the first of their kind, to treat patients aged 12 years and older with sickle cell disease.

The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.

The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.

The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.

The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.

The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.

The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.